Investigating mutations in human cells to improve safety assessments for genetic risks
Official title: Mutational profiling in human cells as an in vitro alternative to in vivo mutagenicity assessments
Funded at Scitovation, LLC · NIH-10845665 · Data updated 2026-11-12
This study is working on a new way to look at changes in human cells that can help us understand cancer and birth defects better, using advanced technology instead of animal testing, which could lead to safer products and improved health for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scitovation, LLC NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | May 23, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $910,332 |
| NIH project number | 5R44ES035336-02 |
| Project ID | NIH-10845665 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals concerned about genetic risks associated with environmental exposures or treatments that may lead to birth defects.
✕Less likely to help
Patients with conditions unrelated to genetic mutations or those not exposed to potential mutagenic substances may not receive direct benefits from this research.
What this research studies
This research focuses on developing a new method to assess mutations in human cells, which are critical for understanding risks related to cancer and birth defects. By using advanced sequencing techniques, the study aims to create an alternative to traditional animal testing methods that currently assess genetic toxicity. Patients may benefit from this research as it seeks to provide more accurate data on the safety of various substances, potentially leading to better health outcomes. The approach emphasizes the use of human cells to fill existing gaps in regulatory assessments.
Why it matters
Potential benefit: If successful, this research could lead to safer products and treatments by providing more accurate assessments of genetic risks in humans.
How similar studies have gone: Other research has shown promise in using human cell-based assays for mutagenicity assessments, indicating a potential for success with this novel approach.
Where this research is happening
-
Scitovation, LLC
Durham, United States Active
Researchers
- Principal investigator: Recio, Leslie — Scitovation, LLC
- Study coordinator: Recio, Leslie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.